bump after semaglutide injection Dermal Hypersensitivity Reaction to Semaglutide: Two Case Reports Initial presentation of the patient
Description
There may also be an increase in strategic partnerships and acquisitions as companies look to bolster their portfolios with proven subq GLP-1 assets
It can be used off-label to treat other medical conditions, like obesity
GLP-1 medications can be an effective tool for weight loss but require close monitoring and a multidisciplinary approach.
Analysts will be watching as a generic version of semaglutidemarketed by Novo Nordisk as Wegovy for weight losslaunches in Canada as a test case for future price erosion in the U.S.
Eli Lillys first nine months of 2025 underscored the scale of the GLP-1 surge: Mounjaro and Zepbound generated $39.5 billion in revenue and surpasses Mercks Keytruda as the worlds best-selling medicine[5]
A narrow 107 vote ended GLP-1 coverage for state employees, citing high premium costs and a tight state budget.
